Search
Paclitaxel Treatment Options
A collection of 2017 research studies where Paclitaxel is the interventional treatment. These studies are located in the United States. Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.
1213 - 1224 of 2017
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
Withdrawn
The purpose of this study is to see if a combination of paclitaxel protein bound (also known as nab-paclitaxel), gemcitabine, and cisplatin when given with high dose Ascorbic Acid will be safe and effective in individuals with untreated metastatic pancreatic cancer.
Vitamin C is a nutrient found in food and dietary supplements. It protects cells and also plays a key role in making collagen (which provides strength and structure to skin, bones, tissues and tendons). High-dose vitamin C may be gi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2019
Locations: Piedmont Cancer Institute, Atlanta, Georgia +2 locations
Conditions: Metastatic Pancreatic Cancer
Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
Completed
The purpose of this study is to assess safety of nab-paclitaxel based chemotherapy regimens administered prior to and/or in combination with nivolumab in Pancreatic Cancer, Non Small Cell Lung Cancer (NSCLC) and Metastatic Breast Cancer (mBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2019
Locations: UC Davis Cancer Center, Sacramento, California +14 locations
Conditions: Breast Neoplasms, Pancreatic Neoplasms
Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
Withdrawn
This study will investigate the combination of two drugs, trametinib and nab-paclitaxel, in patients with advanced unresectable or metastatic melanoma. Each drug has shown activity in trials of patients with melanoma. However, the combination of these two drugs has not been studied. In this trial the investigators will determine the maximum dose of the drug combination to be administered to patients with advanced unresectable or metastatic melanoma and examine the safety profile of the drug comb... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2019
Locations: Colorado Blood Cancer Institute, Denver, Colorado +2 locations
Conditions: Melanoma
High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
Withdrawn
The purpose of this study is to see if a combination of paclitaxel protein bound (also known as nab-paclitaxel), gemcitabine, and cisplatin when given with high dose Ascorbic Acid will be safe and effective in individuals with untreated metastatic pancreatic cancer.
Vitamin C is a nutrient found in food and dietary supplements. It protects cells and also plays a key role in making collagen (which provides strength and structure to skin, bones, tissues and tendons). High-dose vitamin C may be gi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2019
Locations: HonorHealth Research Institute, Scottsdale, Arizona +5 locations
Conditions: Metastatic Pancreatic Cancer, Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma Resectable, Pancreatic Ductal Adenocarcinoma, Pancreatic Metastasis
Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether receiving combined carboplatin and paclitaxel plus continued low-dose paclitaxel is more effective than carboplatin and paclitaxel alone for early-stage ovarian cancer.
PURPOSE: This randomized phase III trial is studying carboplatin and paclitaxel alone too see how well they work compared to c... Read More
Gender:
FEMALE
Ages:
120 years and below
Trial Updated:
05/23/2019
Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +150 locations
Conditions: Ovarian Cancer
Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA
Completed
The primary objective of this study is to determine the efficacy of nab-paclitaxel plus cisplatin plus gemcitabine for patients with metastatic pancreatic ductal adenocarcinoma (PDA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2019
Locations: Scottsdale Health Care, Scottsdale, Arizona +2 locations
Conditions: Stage IV Pancreatic Cancer
Study of SOR007 Ointment for Actinic Keratosis
Completed
A Phase 2, randomized, double-blind, dose rising study to determine the safety, tolerability, and preliminary efficacy of four concentrations of SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment (SOR007) compared to SOR007 ointment vehicle applied to actinic keratosis (AK) lesions on the face twice daily for up to 28 days.
Gender:
ALL
Ages:
Between 45 years and 85 years
Trial Updated:
05/02/2019
Locations: Moore Clinical Research, Tampa, Florida
Conditions: Actinic Keratosis
Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer
Unknown
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving paclitaxel together with sorafenib may kill more tumor cells.
PURPOSE: This randomized phase II trial is studying how well paclitaxel works when given together with or wit... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
05/01/2019
Locations: Northwest Alabama Cancer Center, PC - Muscle Shoals, Muscle Shoals, Alabama +42 locations
Conditions: Breast Cancer
Evaluation of Safety and Efficacy of Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma
Completed
The purpose of this study is to see how well electrochemotherapy works at treating people with Stage III pancreatic adenocarcinoma. Electrochemotherapy is a treatment that combines electroporation and chemotherapy administration. Electroporation uses an electric current to produce holes in pancreatic tumor, which causes the tumor cells to die or take up a higher concentration of administered chemotherapy agent. This study will test the safety and look at the effect of electrochemotherapy in the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2019
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Pancreatic Adenocarcinoma
Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer
Withdrawn
GAX represents a novel approach to the development of cancer chemotherapy agents in pancreatic cancer and is based upon extensive laboratory investigations for the induction of apoptosis in pancreatic carcinoma cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2019
Locations: Stamford Hospital Bennett Cancer Center, Stamford, Connecticut
Conditions: Pancreatic Cancer
T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer
Completed
This open-label, single-center Phase Ib study will assess the safety and tolerability of combining trastuzumab emtansine (T-DM1) with Lapatinib and Abraxane in patients with metastatic HER2-positive breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2019
Locations: Houston Methodist Hospital, Houston, Texas
Conditions: Metastatic Breast Cancer
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Completed
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is most effective in treating ovarian epithelial cancer and peritoneal cancer. Randomized phase III trial to compare the effectiveness of various combination chemotherapy regimens in treating patients who have stage III or stage IV ovarian cancer or primary peritoneal cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
04/03/2019
Locations: Gynecologic Oncology Group, Philadelphia, Pennsylvania
Conditions: Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer
1213 - 1224 of 2017